Peer-reviewed veterinary case report
Chemo drugs tested on canine transmissible venereal tumor cells
By Franco Molina, Moisés Armides et al.·Published in Frontiers in veterinary science·2022·Laboratorio de Inmunologí·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: chemosensitivity of a canine tumor venereal transmissible cancer cell line.
- Species:
- dog
Plain-English summary
A dog with a common type of cancer called transmissible venereal tumor (TVT) was studied to find effective treatments. Researchers tested several chemotherapy drugs to see how well they could kill cancer cells. They found that all the drugs helped reduce the cancer cell growth, but vincristine was still the most effective on its own. Additionally, when vincristine was combined with another drug called toceranib, it worked even better. This suggests that using vincristine along with toceranib could be a promising treatment option for dogs with this type of cancer.
People also search for: dog cancer treatment options · vincristine for dog tumor · toceranib and vincristine for TVT
Abstract
The canine transmissible venereal tumor (CTVT) is the most common malignity in dogs. Because there are reports that this tumor is resistant to vincristine sulfate, the chemotherapeutic options are scarce, and the development of new therapeutic approaches is necessary. In this study, we evaluated the cytotoxic activity of vincristine, doxorubicin, temozolomide, panobinostat, toceranib, gemcitabine, cisplatin, fluorouracil, cyclophosphamide, and methotrexate on a CTVT cell line, determining that all drugs decreased the viability in a dose-dependent manner. Furthermore, they inhibit cellular migration in a time- and drug-dependent manner, as evaluated by the wound healing assay. On the other hand, vincristine, panobinostat, gemcitabine, toceranib, cyclophosphamide, and methotrexate increased the percentage of cells in the subG1 phase, and doxorubicin, temozolomide, gemcitabine, toceranib, and methotrexate decreased the percentage of cells in the synthesis phase. To efficientize the use of vincristine, only toceranib increased the cytotoxic effect of vincristine in a synergistic manner. Our results confirm the use of vincristine as the gold standard for CTVT treatment as monotherapy and suggest the use of a combinatorial and sequential treatment with toceranib.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/36061122/